Bristol Myers Squibb presented Phase 3 SUCCESSOR-2 data showing mezigdomide improved progression-free outcomes in relapsed/refractory multiple myeloma when added to carfilzomib and dexamethasone. The regimen cut the risk of disease progression or death by 52% versus the background therapy, and BMS reported a median PFS of 18 months versus 8.3 months. Separately, Pfizer disclosed detailed Phase 3 TALAPRO-3 results of TALZENNA (talazoparib) plus XTANDI (enzalutamide) in HRR gene-mutated metastatic castration-sensitive prostate cancer. The combination reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI, with three-year rPFS estimated at 77% versus 56%.